Theralase Technologies Inc. (TLT.V)
| Previous Close | 0.1650 |
| Open | 0.1600 |
| Bid | 0.1600 x 0 |
| Ask | 0.1700 x 0 |
| Day's Range | 0.1600 - 0.1650 |
| 52 Week Range | 0.1600 - 0.3100 |
| Volume | |
| Avg. Volume | 131,120 |
| Market Cap | 38.796M |
| Beta (5Y Monthly) | 1.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings Date | May 28, 2024 - Jun 03, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ACCESSWIRETheralase(R) Closes $CAN 750,000 Non-Brokered Private Placement
TORONTO, ON / ACCESSWIRE / April 24, 2024 / Theralase® Technologies Inc. ("Theralase® " or the "Company") (TSXV:TLT)(OTCQB:TLTFF)(FRA:TTX), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation ...
- ACCESSWIRE
Theralase(R) Granted Canadian Cancer Vaccine Patent
TORONTO, ON / ACCESSWIRE / April 5, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated ...
- ACCESSWIRE
Theralase(R) Release's 4Q2023 Interim Financial Statements
TORONTO, ON / ACCESSWIRE / March 27, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated ...
